Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022
- After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia.
- The submission is currently anticipated in the fourth quarter of 2022, pending completion of manufacturing and other activities related to the product candidate.
- AXS-14 has completed two positive placebo-controlled trials, a Phase 3 and a Phase 2 trial, which will be included in the submission.
- Fibromyalgia is a chronic debilitating disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.
- Approximately 5 million Americans are estimated to suffer from fibromyalgia, with treatment options limited with only three pharmacologic treatments currently approved by the FDA.
- Price Action: AXSM shares are up 2.6% at $69.28 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs fibromyalgiaBiotech News Health Care FDA General
